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Original investigation
1)
Introduction
A third of peritoneal dialysis (PD) patients are fre-
quently hypokalemic, in whom potassium removal by PD
does not explain the occurrence of hypokalemia
1, 2). Spital
and Sterns noted that 36% of PD patients had a serum
potassium level less than 3.5 mEq/L at some time during
their course and that 20% required potassium supplementa-
tion
3). Serum potassium levels in PD patients may be influ-
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enced by nutritional status and severity of coexisting co-
morbid conditions. Furthermore, hypokalemia was an in-
dependent predictor of mortality in PD patients
4).
Tziviskou et al. suggested that hypokalemia in PD pa-
tients could be due to a shift of potassium into the intra-
cellular space, probably because of insulin release during
the continuous dwell of the dialysis solution containing
glucose
5). Thus, cellular uptake may play an important role
in the pathogenesis of hypokalemia. Muscle biopsy studies
showed that PD patients had a higher intracellular potas-
sium content than hemodialysis patients
6). Ongoing loss of
potassium in dialysate may be another important con-
tributing factor to hypokalemia
4). In addition, end stage re-
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Hypokalemia occurs frequently in patients undergoing peritoneal dialysis (PD). However, the therapeutic
strategy may differ from that of non-PD-related hypokalemia. We investigated clinical features and related
factors of de novo hypokalemia in incident PD patients. We retrospectively enrolled 82 normokalemic pa-
tients starting PD at Gachon University Gil Hospital, Korea. The patients were divided into hypokalemia
(K
+<3.5 mEq/L) and normokalemia (3.5 mEq/L K ≤
+<5.5 mEq/L) groups based on the plasma potassium levels
at month 13, and then clinical parameters including peritoneal function and adequacy tests and biochemical
parameters were compared. Eight patients who showed hyperkalemia (K
+ 5.5 mEq/L) at month 13 were ≥
excluded from our analyses. The incidence of hypokalemia in PD patients was 7.3% in a year. The de
novo hypokalemia (n=6) and normokalemia (n=68) groups had no significant differences in baseline
characteristics. The serum albumin levels and normalized protein equivalent of nitrogen appearance (nPNA)
at month 1 were not significantly different between the two groups. At month 13, on the other hand, serum
albumin levels and nPNA were significantly lower in the hypokalemia group (P=0.014; P=0.006, respec-
tively). Kt/Vurea, residual renal function, dialysate-peritoneal creatinine ratio, and glucose load were not
significantly different between the two groups. Hypokalemia occurring after initiation of PD may largely
be associated with poor nutritional status.
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nal disease (ESRD) patients are instructed to restrict potas-
sium-rich foods such as fruits and vegetables.
Most previous studies enrolled small numbers of pa-
tients, and were cross sectional studies. To the best of our
knowledge, no longitudinal studies were reported to define
the characteristics of hypokalemia in a PD population. This
study was undertaken to investigate clinical features and
related factors of de novo hypokalemia in incident PD pa-
tients over the 1-year observational period.
Materials and Methods
This study was conducted at our PD center in Gachon
University Gil Hospital, Korea. Eighty-two incident PD pa-
tients were enrolled, who were normokalemic at month 1
of PD. According to the plasma potassium levels at month
13, the patients were divided into hypokalemia (K
+<3.5
mEq/L) and normokalemia (3.5 mEq/L K
+<5.5 mEq/L)
groups. Eight patients who showed hyperkalemia (K
+ 5.5
mEq/L) at month 13 were excluded. Different PD fluids
(Baxter Healthcare, Deerfield, IL, USA and Fresenius
Medical Care Deutschland GmbH, Bad Homburg, Ger-
many) were used as either conventional or biocompatible
solutions.
Blood, urine and PD effluent samples were taken on
3 occasions during the study: baseline, after the 4-week
break-in period (at month 1), and after 12 months (at month
13) of starting PD. Peritoneal function tests for measure-
ment of dialysis adequacy, peritoneal equilibration test
(PET) and Kt/V (where K is the dialyzer clearance of urea,
t is the dialysis time, and V is the patient’s total body
water) were taken at months 1 and 13. The values of the
glomerular filtration rate (GFR), PET, Kt/V, and other lab-
oratory parameters measured at month 1 were regarded as
baseline. Information collected at the start of the study in-
cluded age, gender, weight, height, underlying renal dis-
ease, and comorbidity. The degree of comorbidity was as-
sessed using the Davies comorbidity score, which com-
prises seven comorbid conditions-malignancy, ischemic
heart disease, peripheral vascular disease, left ventricular
dysfunction, diabetes mellitus, systemic collagen vascular
disease, and others (chronic obstructive pulmonary disease,
liver cirrhosis, and asthma). Patients were divided into
three risk groups: low (no comorbid disease), intermediate
(1 or 2 comorbid diseases), and high ( 3 comorbid dis-
eases)
7).
Dialysis adequacy and nutritional status data were ex-
pressed as the Kt/V urea and normalized protein equivalent
of nitrogen appearance (nPNA; g/kg/day), respectively.
The urea distribution volume was calculated using the
Watson equation
8). The 24-h collection of dialysate effluent
was used to calculate the peritoneal Kt/V urea. The total
Kt/V urea was calculated as the sum of the renal and peri-
toneal Kt/V urea. When the modified PET using 3.86%
glucose solution was performed, the results for the Korean
PD patients were similar to those of Caucasian patients
9).
After an overnight dwell with 1.36% glucose PD fluid,
the patients were subjected to a 4-h dwell with dialysis
fluid containing 3.86% glucose. Blood samples were taken
after 2 hours. The dialysate-to-plasma creatinine (D/P Cr)
was calculated as the dialysate concentration at 4 hours
divided by the plasma creatinine concentration. The dialy-
sate creatinine concentration was determined after correct-
ing for glucose interference. The daily glucose load (g/day)
was calculated as the sum of the product of the volume
and the glucose concentration for all of the daily bags.
The baseline GFR was estimated from serum creatinine
using the abbreviated Modification of Diet in Renal
Disease (MDRD) study formula. Residual renal function
(RRF) was assessed by collecting all urine output over the
same 24-h period during which dialysate was collected;
GFR was calculated as the mean of the values for crea-
tinine and urea clearances.
Biochemical tests were performed using a Roche modu-
lar units analyzer (Toshiba 200FR, Toshiba Medical Sys-
tems, Tokyo, Japan). Serum C-reactive protein (CRP) lev-
els were determined using an immunoturbidimetric method
(Denka Seiken, Tokyo, Japan). Indirect ion selective elec-
trode methods were used to determine the electrolyte lev-
els, and an enzymatic method was used to measure the
total CO2.
The values were presented as median (interquartile
range) values. To compare differences between the hypo-JY Jung et al. : De novo Hypokalemia in Incident PD 75
kalemia and normokalemia groups, Mann-Whitney U test
and the chi- square test were used. When comparing paired
samples, Wilcoxon signed ranks test was applied for con-
tinuous variables. The data were analyzed using SPSS 12.0
for Windows (SPSS Inc., Chicago, IL, USA) and P<0.05
was considered significant.
Results
The baseline demographics of the patients starting PD
are presented in Table 1. The two groups with and without
hypokalemia had no significant differences in age, sex,
height, and causes of end-stage renal disease. Medication
history of angiotensin converting enzyme inhibitors or an-
Table 1. Baseline Demographics
De novo Hypokalemia (N=6) Normokalemia (N=68) P
Age (year)
Male (%)
Height (cm)
Causes of ESRD (%)
Diabetes mellitus
Hypertension
Glomerulonephritis
Others
Drug history (%)
ACEI/ARB
Diuretics
Davies comorbidity (%)
Low
Intermediate
High
Biocompatible fluid (%)
CAPD (%)
eGFR at month 0 (mL/min/1.73m
2)
58.7 (43.3-76.4)
4 (66.7)
164 (158-169)
5 (83.3)
0
1 (16.7)
0
6 (100)
3 (50.0)
1 (16.7)
3 (50.0)
2 (33.3)
2 (33.3)
6 (100)
6.44 (3.91-8.98)
53.0 (45.2-60.5)
41 (60.3)
165 (158-170)
28 (41.2)
26 (38.2)
5 (7.4)
9 (13.2)
65 (95.6)
35 (51.5)
23 (33.8)
43 (63.3)
2 (2.9)
26 (38.2)
66 (97.1)
6.97 (5.20-9.18)
0.337
0.761
0.886
0.118
0.599
0.945
0.054
0.812
0.670
0.692
ESRD, end stage renal disease; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockades; CAPD,
continuous ambulatory peritoneal dialysis; eGFR, estimated glomerular filtration rate by MDRD equation.
Table 2. Serum Parameters at Months 1 and 13
Month 1 Month 13
Hypokalemia (N=6) Normokalemia (N=68) Hypokalemia (N=6) Normokalemia (N=68)
C-reative protein (mg/dL)
Glucose (mg/dL)
Uric acid (mg/dL)
BUN (mg/dL)
Creatinine (mg/dL)
Protein (g/dL)
Albumin (g/dL)
Cholesterol (mg/dL)
Sodium (mEq/L)
Potassium (mEq/L)
Chloride (mEq/L)
Total CO2 (mEq/L)
Calcium (mg/dL)
Phosphorus (mg/dL)
Hemoglobin (g/dL)
0.53 (0.11-0.84)
158.5 (106.5-264.5)
8.9 (8.0-9.9)*
65.8 (32.3-74.6)
7.6 (6.4-10.3)
6.2 (6.0-6.6)
3.1 (2.8-3.7)
125.0 (123.0-148.0)*
136.0 (134.5-138.5)
4.1 (3.8-4.3)
101.5 (96.0-102.5)
19.5 (19.0-20.0)
8.5 (7.1-11.5)
5.6 (4.8-6.1)*
10.7 (8.3-10.9)
0.15 (0.09-0.34)
138.5 (105.5-218)
7.1 (6.3-8.3)
49.9 (40.3-59.1)
7.6 (5.9-9.5)
6.6 (6.1-6.9)
3.7 (3.3-3.9)
163.5 (146.5-187.8)
139.0 (136.0-141.0)
4.2 (4.0-4.7)
102.0 (99.3-103.8)
23.0 (20.9-25.0)
8.5 (8.1-9.1)
4.2 (3.7-4.9)
11.1 (9.6-11.9)
0.36 (0.13-2.40)
37.5 (94.3-309)
6.25 (5.8-7.1)
37.0 (28.4-57.3)
8.6 (6.9-9.9)
5.6 (5.4-6.6)
2.9 (2.5-3.7)*
163.0 (128.5-203.5)
136.0 (133.5-142.5)
3.4 (3.2-3.5)*
†
98.0 (96.0-103.0)
23.5 (21.0-26.0)
8.6 (7.8-9.2)
3.7 (3.1-5.1)
9.7 (8.5-11.3)
0.18 (0.10-0.69)
127.5 (101.3-157.3)
7.1 (6.3-8.1)
53.5 (42.4-65.5)
9.4 (7.1-12.2)
6.5 (6.1-6.9)
3.7 (3.4-4.1)
174.0 (154.5-201.5)
139.0 (137.0-140.0)
4.5 (4.0-4.9)
101.0 (98.0-103.0)
22.1 (19.9-25.2)
8.9 (8.3-9.3)
4.6 (3.9-5.7)
10.4 (9.8-11.3)
BUN, blood urea nitrogen.
*P<0.05, hypokalemia group vs. normokalemia group by Mann-Whitney U test.
†P<0.05, month 1 vs. month 13 in each group by Wilcoxon signed rank test.76 Electrolyte Blood Press 7:73-78, 2009
giotensin II receptor blockades and diuretics were not sig-
nificantly different between the two groups. No statistical
differences were found between the two groups with re-
spect to the Davies comorbidity, biocompatible fluid, and
CAPD versus automated PD, although the hypokalemia
group showed a higher propensity for diabetes mellitus.
Table 2 shows the biochemical parameters. The in-
cidence of hypokalemia in patients starting PD was 7.3%
over the 1-year observation. Whereas the initial serum po-
tassium and albumin levels at month 1 were not different
between the two groups, the serum albumin level in the
hypokalemia group significantly decreased from 3.1 (2.8-
3.7) to 2.9 (2.5-3.7) mg/dL at month 13 (P=0.014). In con-
trast, no significant differences were observed in the serum
glucose, CRP, protein, cholesterol, and total CO2 between
the two groups at month 13. At month 1, the hypokalemia
group had a higher serum phosphorus level and lower uric
acid and cholesterol levels.
Peritoneal function and adequacy tests were measured
at months 1 and 13 (Table 3). At month 1, the two groups
showed no significant differences. The nPNA at month 1
was also similar between the hypokalemia and normokale-
mia groups [0.89 (0.57-1.09) and 0.91 (0.77-1.01) g/kg/
day]. At month 13, however, the nPNA was significantly
lower in the hypokalemia group [0.66 (0.58-0.79) g/
kg/day] compared to that in the normokalemia group [0.91
(0.82-1.02) g/kg/day]. Other measurements determined for
peritoneal function such as D/P Cr and daily glucose load
were not different between the two groups.
Discussion
The present study demonstrates that the development
of hypokalemia may not be uncommon in incident PD pa-
tients and can be associated with decreases in serum albu-
min and nPNA. The incidence of hypokalemia in our PD
patients, 7.3% in a year, appears relatively low compared
with that of previous reports
1, 2, 10). This is probably be-
cause our result was from newly starting PD patients.
We showed that the development of hypokalemia was as-
sociated with a lower serum albumin level. Hypoalbumine-
mia may be the strongest independent risk factor for death
in CAPD patients
11). Albumin is a negative acute phase
reactive protein
12), and albumin synthesis should be sup-
pressed under some inflammatory conditions. In our study,
however, CRP did not differ between the two groups.
Malnutrition causes decreased albumin synthesis as well
and is a potential cause of decreased albumin levels and
increased morbidity and mortality in ESRD
13).
We also found that nPNA was significantly lower in the
hypokalemia group at month 13. This is important be-
cause nPNA is a marker for nutrition and a well-known
predictor of mortality in PD patients. Pérez-Flores et al.
showed that nPNA is directly correlated with RRF and
that RRF is correlated with CRP as well
14). In the present
Table 3. Peritoneal Function and Adequacy Tests at Months 1 and 13
Month 1 Month 13
Hypokalemia (N=6) Normokalemia (N=68) Hypokalemia (N=6) Normokalemia (N=68)
D/P Cr
D/D0 glucose
Ultrafiltration capacity (mL)
Weight (kg)
Urine volume (mL/day)
nPNA (g/kg/day)
Total Kt/V urea
GFR (L/week/1.73m
2)
Glucose exposure (g/day)
0.68 (0.61-0.81)
0.43 (0.32-4.50)
675 (538-925)
63.8 (58.9-70.0)
350 (165-950)
0.89 (0.57-1.09)
2.37 (1.76-2.82)
47.02 (35.62-55.49)
130 (120-140)
0.67 (0.61-0.76)
0.43 (0.32-0.63)
850 (550-1000)
66.0 (58.0-71.8)
600 (438-1200)
0.91 (0.77-1.01)
2.05 (1.65-2.53)
41.16 (34.52-45.09)
120 (90-140)
0.69 (0.67-0.81)
0.29 (0.18-0.55)
800 (575-825)
66.0 (53.5-67.5)
340 (20-810)
0.66 (0.58-0.79)
1.94 (1.63-2.07)
48.52 (41.49-50.66)
163 (110-215)
0.67 (0.61-0.74)
0.31 (0.27-0.34)
†
800 (625-1000)
63.6 (56.4-68.0)
550 (275-925)
0.91 (0.82-1.02)*
1.98 (1.71-2.35)
42.65 (36.78-47.86)
120 (95-140)
D/P Cr, dialysate to plasma creatinine ratio at 4 hours; D/D0 glucose, ratio of dialysate glucose at 4 hours' dwell time to dialysate
glucose at 0 dwell time; nPNA, protein equivalent of total nitrogen appearance normalized to desirable body weight (generating
rate of urea); GFR, glomerular filtration rate (calculated as the mean of the values for creatinine and urea clearances).
*P<0.05, hypokalemia group vs. normokalemia group by Mann-Whitney U test.
†P<0.05, month 1 vs. month 13 in each group by Wilcoxon signed rank test.JY Jung et al. : De novo Hypokalemia in Incident PD 77
study, however, no difference was observed in RRF be-
tween the two groups.
Potassium homeostasis is maintained by two different
balances: the internal balance representing potassium redis-
tribution between the intracellular and the extracellular
compartments, and the external balance representing potas-
sium interchanges between the organism and the environ-
ment
15). In PD patients, Tziviskou et al. suggested that in-
sulin hormone, stimulated by the continuous glucose peri-
toneal dwell, could generate an increase of potassium redis-
tribution into the intracellular compartment
5). Some authors
have postulated a dysfunction in the cellular Na
+,K
+-
ATPase pump as the cause of their low intracellular potas-
sium content
16). In the present study, the presence of dia-
betes and daily glucose load were not different between
the two groups, suggesting that intracellular potassium re-
distribution may not be the main mechanism of hypo-
kalemia in our PD patients.
Kim et al. reported in a cross-sectional design that the
serum potassium level of PD patients was correlated with
ultrafiltration volume at the PET and serum albumin lev-
el
10). However, our patients had no difference in ultra-
filtration volume at month 13. It is conceivable that
changes in ultrafiltration volume may occur after the
change in serum albumin level. Even though long-term fol-
low up of a large number of patients would be needed
to elucidate this mechanistic relationship, it emphasizes the
importance of serum potassium level as a nutritional mark-
er as well as a potential predictor of outcome.
In addition, variables regarding peritoneal function and
adequacy tests were not different between patients with
or without hypokalemia, suggesting that the role of peri-
toneal potassium loss in producing hypokalemia may not
be substantial. Unfortunately, however, we did not examine
urinary and peritoneal dialysate potassium concentrations
from our patients. Thus, the possibility of increased potas-
sium loss in dialysate and urine in hypokalemic patients
cannot completely be excluded. Detailed dietary assess-
ment should be of help for the proper evaluation of potas-
sium balance disturbances.
Higher serum phosphorus levels and lower uric acid and
cholesterol levels were noted at month 1 in the hypo-
kalemia group. The reason why those serum levels were
different between the two groups is not clear, but may be
associated with poor general conditions in hypokalemia
patients.
In summary, we investigated clinical features of PD-as-
sociated hypokalemia and found that development of hypo-
kalemia was associated with a lower serum albumin level
and decreased nPNA in new PD patients. Therefore, we
suggest that serum potassium levels should be monitored
more carefully in PD patients with poor nutritional status.
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